Communiqués Orexo AB

Actions

Marché Fermé - Nasdaq Stockholm 18:00:00 31/08/2026			Varia. 5j.	Varia. 1 janv.
15,70 ^SEK	+17,34 %		+17,16 %	-47,84 %

31/08	La Bourse de Stockholm entame la semaine en baisse, l'indice OMXS30 recule de 0,7 %	FW
31/08	Séance irrégulière à la Bourse de Stockholm, l'indice OMXS30 recule de 0,2 %	FW

31/08	Orexo: Highlights from DNB Carnegie’s Micro Cap Day	AQ
31/08	Orexo: Reaches a non-binding settlement with DOJ	AQ
31/08	Orexo reaches non-binding agreement in principle to settle investigation by US Department of Justice	AQ
17/07	Orexo: Weak Q2, with potential H2 catalysts nearing – Q2 review	AQ
16/07	Orexo : Audiocast (engelska)	PU
16/07	Orexo Q2 2026 Interim Report	AQ
09/06	Orexo appoints Raheleh Nassaji as SVP Business Development, strengthening its focus on new partnerships	AQ
19/05	Orexo: Promising early-stage data	AQ
19/05	Orexo announces positive outcome from an in-vivo study of OX390	AQ
07/05	Report from Orexo AB’s annual general meeting May 7 2026	AQ
29/04	Orexo: Better visibility, few near-term catalysts – Q1 review	AQ
28/04	Orexo : Earnings Call Q1 2026 (engelska)	PU
28/04	Orexo : Earnings Call Q1 2026	PU
28/04	Orexo : Q1 2026 Interim Report MASTER	PU
28/04	Orexo : Q1 2026 Interim Report 2026	PU
28/04	Orexo : Audiocast	PU
28/04	Orexo Q1 2026 Interim Report	AQ
21/04	Invitation to presentation of Orexo´s Q1 2026 Interim Report	AQ
31/03	Number of shares and votes in Orexo	AQ
30/03	Notice of Annual General Meeting of Orexo	AQ
27/03	Orexo : Sustainability Report 2025	PU
27/03	Orexo publishes Annual Report for 2025	AQ
24/03	Orexo: Key takeaways from R&D Day	AQ
24/03	Orexo R&D Day - Building global leadership in amorphous drug delivery	AQ
06/03	Invitation & Agenda: Orexo R&D Day on March 24	AQ